Scholarlink

Objectives <p>To evaluate the technical parameters and clinical outcomes of contrast-enhanced mammography (CEM)-guided biopsy for diagnosing breast cancer in patients with suspicious lesions showing post-contrast enhancement on CEM but undetectable on standard digital mammography (DM) or ultrasound (US).</p> Materials and methods <p>A prospective study was conducted on 36 patients referred for CEM-guided biopsy based on suspicious (BI-RADS 4-5) enhancing-only lesions detected during previous CEM examinations and/or contrast-enhanced breast MRI (CE-MRI). Procedures were performed on a dedicated prone table using a vacuum-assisted biopsy device. Effectiveness parameters included success rate (lesion enhancement, diagnostic material collection, and correct clip positioning), procedure time, average glandular dose (AGD), compression force, and complication rate.</p> Results <p>From January to November 2024, 36 patients underwent CEM-guided biopsy, with a success rate of 97.2% (35/36). The median procedure time was 29 min. The AGD was 0.88 mGy (range 0.5–1.4 mGy, SD ± 0.22). The average compression force was 4.94 kg (range 2–7 kg, SD ± 1.1). Of the 35 lesions biopsied, 20 (57.1%) were masses and 15 (42.9%) non-mass enhancements, with a mean lesion size of 13.2 mm. Breast lesions were classified as BIRADS 4a (10/35), BIRADS 4b (5/35), BIRADS 4c (8/35), and BIRADS 5 (12/35). Histopathological findings showed 57.1% (20/35) of lesions were malignant. Lesion classification included 5.7% (B1), 34.3% (B2), 2.9% (B3), 31.4% (B5a), and 25.7% (B5b).</p> Conclusion <p>CEM-guided biopsy is an effective and accessible technique for targeting enhancing-only breast lesions, offering advantages over MRI-guided biopsy in terms of time, cost, and patient comfort.</p> Critical relevance statement <p>Contrast-enhanced mammography-guided biopsy is an effective and accessible technique for targeting enhancing-only breast lesions, offering advantages over MRI-guided biopsy in terms of time, cost, and patient comfort.</p> Key Points <p><UnorderedList Mark="Bullet"> <ItemContent> <p>Contrast-enhanced mammography (CEM)-guided biopsy has recently gained traction as a reliable alternative to MRI for targeting enhancing-only lesions.</p> </ItemContent> <ItemContent> <p>This study explores the clinical implementation of CEM-guided biopsy in a prone position in our university hospital, assessing its efficacy, safety, and diagnostic accuracy.</p> </ItemContent> <ItemContent> <p>CEM-guided biopsy is a promising technique for the precise targeting of breast lesions, with advantages over MRI-guided biopsy.</p> </ItemContent> </UnorderedList></p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Contrast-enhanced mammography-guided biopsy in a prone position in the diagnosis of breast cancer: technical parameters and clinical outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月17日

查看全文
  • Giulia Morano,
  • Federica Cicciarelli,
  • Giuliana Moffa,
  • Giacomo Bonito,
  • Veronica Rizzo,
  • Alessandro Calabrese,
  • Francesca Galati,
  • Federica Pediconi

摘要

Objectives

To evaluate the technical parameters and clinical outcomes of contrast-enhanced mammography (CEM)-guided biopsy for diagnosing breast cancer in patients with suspicious lesions showing post-contrast enhancement on CEM but undetectable on standard digital mammography (DM) or ultrasound (US).

Materials and methods

A prospective study was conducted on 36 patients referred for CEM-guided biopsy based on suspicious (BI-RADS 4-5) enhancing-only lesions detected during previous CEM examinations and/or contrast-enhanced breast MRI (CE-MRI). Procedures were performed on a dedicated prone table using a vacuum-assisted biopsy device. Effectiveness parameters included success rate (lesion enhancement, diagnostic material collection, and correct clip positioning), procedure time, average glandular dose (AGD), compression force, and complication rate.

Results

From January to November 2024, 36 patients underwent CEM-guided biopsy, with a success rate of 97.2% (35/36). The median procedure time was 29 min. The AGD was 0.88 mGy (range 0.5–1.4 mGy, SD ± 0.22). The average compression force was 4.94 kg (range 2–7 kg, SD ± 1.1). Of the 35 lesions biopsied, 20 (57.1%) were masses and 15 (42.9%) non-mass enhancements, with a mean lesion size of 13.2 mm. Breast lesions were classified as BIRADS 4a (10/35), BIRADS 4b (5/35), BIRADS 4c (8/35), and BIRADS 5 (12/35). Histopathological findings showed 57.1% (20/35) of lesions were malignant. Lesion classification included 5.7% (B1), 34.3% (B2), 2.9% (B3), 31.4% (B5a), and 25.7% (B5b).

Conclusion

CEM-guided biopsy is an effective and accessible technique for targeting enhancing-only breast lesions, offering advantages over MRI-guided biopsy in terms of time, cost, and patient comfort.

Critical relevance statement

Contrast-enhanced mammography-guided biopsy is an effective and accessible technique for targeting enhancing-only breast lesions, offering advantages over MRI-guided biopsy in terms of time, cost, and patient comfort.

Key Points

Contrast-enhanced mammography (CEM)-guided biopsy has recently gained traction as a reliable alternative to MRI for targeting enhancing-only lesions.

This study explores the clinical implementation of CEM-guided biopsy in a prone position in our university hospital, assessing its efficacy, safety, and diagnostic accuracy.

CEM-guided biopsy is a promising technique for the precise targeting of breast lesions, with advantages over MRI-guided biopsy.

Graphical Abstract